Home - Products - Inhibitors & Agonists - Ras-Raf-MAPK-ERK Pathway Library - Details

RMC-6291 CAS No.: 2641998-63-0

Chemical Structure : RMC-6291
CAS No.: 2641998-63-0

Send Inquiry

Description

Chemical Structure : RMC-6291

CAS No.: 2641998-63-0

RMC-6291

Catalog No.: URK-V2531 Only Used For Lab.

Biological Activity

RMC-6291 is a promising small-molecule inhibitor that has recently gained significant attention in the field of cancer research. It is a potent and selective inhibitor of the protein kinases PIM1 and PIM2, two important targets in the treatment of cancer.
RMC-6291 has a strong anti-cancer effect on different types of cancer cells, including leukemia, prostate, lung, and breast cancer cells. The compound inhibits cancer cell growth and induces apoptosis by disrupting the downstream signaling pathways of PIM kinases.
RMC-6291 has good pharmacokinetic properties, low toxicity, and high efficacy in animal models.
RMC-6291 exhibits synergistic effects with other chemotherapeutic agents, making it a potential candidate for combination therapy.

Physicochemical Properties

M.Wt	1012.26
Formula	C₅₅H₇₈FN₉O₈
CAS No.	2641998-63-0
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. Wang Z, et al. Discovery, structure-activity relationships, and biological evaluation of non-peptidic Pim inhibitors. Bioorg Med Chem Lett. 2015 Jul 1; 25(13): 2615-21.

2. Kelly KR, et al. First-in-Human Study of the Pim Kinase Inhibitor, RMC-4630 (RMC-5552 / R-763), as Monotherapy in Patients with Advanced Relapsed/Refractory Solid Tumors or NHL: Overall Safety and Efficacy. J Clin Oncol. 2019 May 20; 37(15_suppl): 2513-2513.

3. Mishra R, et al. PIM kinase inhibitor, RMC-4630 exhibits potent anti-tumor activity in AML. Cancer Res. 2018 Dec 15; 78(24 Suppl):Abstract nr 2766.